{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:25:29Z","timestamp":1787538329158,"version":"build-2736575974"},"reference-count":11,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Burosumab is a well-established treatment for X-linked hypophosphatemia (XLH), but safety data during pregnancy are limited. We present the case of a woman in her 30s with XLH who continued to take burosumab during pregnancy to prevent symptomatic relapse. She gave birth to a male infant via cesarean section at 37 weeks without obstetric complications. The neonate exhibited a markedly elevated intact fibroblast growth factor 23 level {48 700\u2005pg\/mL (SI: 1933\u2005pmol\/L) (reference range, 19.9-52.9\u2005pg\/mL [SI: 0.79-2.10\u2005pmol\/L])} shortly after birth. This level declined rapidly to 151\u2005pg\/mL (SI: 4.7\u2005pmol\/L) by age 7 months but remained above the normal range. Genetic testing revealed a phosphate-regulating endopeptidase, X-linked gene mutation in both mother and child. The infant was initially managed with conventional therapy before transitioning to burosumab at 8 months of age. At the 1-year follow-up, the child demonstrated no apparent developmental delay or adverse skeletal events. This case presents real-world evidence of continued burosumab exposure during pregnancy in a woman with XLH. Although no apparent short-term maternal or fetal adverse events were observed, the safety of burosumab use during pregnancy is uncertain, and more clinical data, particularly with long-term follow-up, are needed.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag233","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:21:05Z","timestamp":1786706465000},"source":"Crossref","is-referenced-by-count":0,"title":["Continuation of burosumab during pregnancy in a patient with X-linked hypophosphatemia"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0807-199X","authenticated-orcid":false,"given":"Atsushi","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, Fujita Health University School of Medicine , Toyoake, Aichi 470-1192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Fujita Health University School of Medicine , Toyoake, Aichi 470-1192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Nishizawa","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"issue":"3","key":"2026082322030018800_luag233-B1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026082322030018800_luag233-B2","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026082322030018800_luag233-B3","doi-asserted-by":"crossref","first-page":"e001714","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomized phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"issue":"1","key":"2026082322030018800_luag233-B4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00223-025-01359-9","article-title":"Prevalence of comorbid hyperparathyroidism and its association with renal dysfunction in Asian patients with X\u2013linked hypophosphatemic rickets\/osteomalacia","volume":"116","author":"Ito","year":"2025","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"2026082322030018800_luag233-B5","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1210\/clinem\/dgaf170","article-title":"X-linked hypophosphatemia management in adults: an international working group clinical practice guideline","volume":"110","author":"Khan","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026082322030018800_luag233-B6","doi-asserted-by":"crossref","first-page":"e10744","DOI":"10.1002\/jbm4.10744","article-title":"Asia-Pacific consensus recommendations on X-linked hypophosphatemia: diagnosis, multidisciplinary management, and transition from pediatric to adult care","volume":"7","author":"Munns","year":"2023","journal-title":"JBMR Plus"},{"issue":"2","key":"2026082322030018800_luag233-B7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1297\/cpe.25.71","article-title":"Growth standard charts for Japanese children with mean and standard deviation (SD) values based on the year 2000 national survey","volume":"25","author":"Isojima","year":"2016","journal-title":"Clin Pediatr Endocrinol"},{"issue":"11","key":"2026082322030018800_luag233-B8","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1515\/cclm-2020-0460","article-title":"FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference","volume":"58","author":"Piketty","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"2026082322030018800_luag233-B9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/cen.14832","article-title":"The effect of burosumab on intact and C-terminal FGF23 measurements","volume":"99","author":"Ashrafzadeh-Kian","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026082322030018800_luag233-B10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/jbmr.3614","article-title":"High incidence of cranial synostosis and Chiari I malformation in children with X-linked hypophosphatemic rickets (XLHR)","volume":"34","author":"Rothenbuhler","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026082322030018800_luag233-B11","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/clinem\/dgad230","article-title":"Burosumab vs phosphate\/active vitamin D in pediatric X-linked hypophosphatemia: a subgroup analysis by dose level","volume":"108","author":"Imel","year":"2023","journal-title":"J Clin Endocrinol Metab"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/9\/luag233\/70766478\/luag233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/9\/luag233\/70766478\/luag233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:03:08Z","timestamp":1787536988000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag233\/8768965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7,27]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag233","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,27]]},"article-number":"luag233"}}